Emergent BioSolutions, the New York Stock Exchange listed developer and manufacturer of vaccines, completed the sale of its travel vaccine business to Bavarian Nordic for an upfront payment of USD 270 million. At closing Emergent received
NewBiologix, a technology company developing a proprietary platform focused on engineering cell lines used to manufacture gene and cell therapies, raised USD 50 million in series A financing. The round was led by Recipharm (an EQT
DSM and Firmenich have successfully concluded their merger announced on 31 May 2022, becoming a powerful creation and innovation partner in nutrition, beauty, and well-being. The EUR 35 billion business combination solidifies their position in the industry.
Homburger acted as counsel to Fluence in connection with certain financing aspects of the acquisition of Nispera. Headquartered in Arlington, USA, Fluence is a global provider of energy storage products, services and digital applications for
Fidinam & Partners, the national and international tax advisory division of the Fidinam Group, appoints two new members to its Board of Directors: Giuseppe Lerose (pictured left) and Marco Moschen (pictured right). Already deputy directors
The CABB Group has successfully concluded its refinancing round. New bonds with a total volume of EUR 670 million and terms until 2028 were successfully placed with institutional investors. The issue comprises two tranches: EUR 420 million with
Baker McKenzie has appointed its new Global Practice Group and Industry Group leaders, important areas of growth for the firm. All appointments will be effective from 1st July 2023. Regarding Switzerland, Intellectual Property partner Eva-Maria Strobel,
Homburger acted as counsel to GTT Communications on certain financing aspects related to its recent restructuring efforts. Homburger acted as counsel to GTT Communications in connection with a term loan credit agreement with Wilmington Savings
Credaris has purchased the credit intermediary CC Crédits Conseils, along with its call center in Tunisia. The acquisition of the 100% of the shares in the Swiss credit intermediary based in Versoix, further consolidates the
Hasten Biopharmaceutic (China) has acquired the commercial rights in China for Rocephin®, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Under the agreement, Hasten acquired Roche’s China mainland rights for
